^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) + AiRuiKang (dalpiciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC).
Published date:
05/25/2023
Excerpt:
Cohort A: HR+ pts received P (320 mg QD) and D (125 mg QD, 21 days on and 7 days off) combined with letrozole (2.5 mg QD)...26 pts had at least one efficacy assessment, and 17 (65.4%) achieved confirmed objective responses. ORR was 66.7% (10/15), 80% (4/5), and 50% (3/6) in cohort A, B, and C, respectively. Among the ITT population, the estimated median PFS was 24.9 mo. (24.9 mo., NR, and 20.2 mo. in cohort A, B, and C, respectively)...Our study shows P and D combined with ET is effective in HR+/HER2+ ABC, providing a chemo-free option to these pts.
Secondary therapy:
letrozole
DOI:
10.1200/JCO.2023.41.16_suppl.e13027
Trial ID:
Source:
Title:
Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
Published date:
03/07/2022
Excerpt:
The confirmed objective response rate (ORR) was 66.7% (95% CI: 38.4% to 88.2%). The confirmed ORR of study treatment as first line (1L) and second line (2L) HER2-targeted therapy was 85.7% (6/7) and 50.0% (4/8), respectively. Median progression-free survival (PFS) was 11.3 months (95% CI: 5.3 months to not reached)....The fully oral combination of dalpiciclib, pyrotinib and letrozole is a promising chemotherapy-sparing treatment option for HER2-positive, HR-positive MBC patients.
Secondary therapy:
letrozole
DOI:
10.3389/fonc.2022.775081
Source:
Title:
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.
Published date:
05/19/2021
Excerpt:
Data from phase Ib showed the triplet combination of pyrotinib, letrozole, and SHR6390 had an acceptable safety profile and encouraging preliminary efficacy, potentially offering a chemotherapy sparing treatment option for patients with HR+/HER2+ MBC.
Secondary therapy:
letrozole
DOI:
10.1200/JCO.2021.39.15_suppl.1035
Trial ID:
Source:
Title:
The Synergistic Effects of SHR6390 Combined With Pyrotinib on HER2+/HR+ Breast Cancer
Published date:
12/16/2021
Excerpt:
We showed that the combination of SHR6390 and pyrotinib synergistically inhibited the proliferation, migration, and invasion of HER2+/HR+ breast cancer cells in vitro.
DOI:
10.3389/fcell.2021.785796
